Skip to main content

Table 3 Indirect comparison in PFS

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

A1.2 (0.46, 3.1)0.65 (0.48, 0.88)0.87 (0.50, 1.5)0.65 (0.29, 1.5)0.91 (0.45, 1.8)0.38 (0.23, 0.65)0.78 (0.37, 1.6)0.73 (0.30, 1.8)0.63 (0.27, 1.5)0.63 (0.27, 1.5)
0.84 (0.33, 2.2)B0.55 (0.22, 1.3)0.73 (0.34, 1.6)0.54 (0.17, 1.8)0.76 (0.24, 2.4)0.32 (0.12, 0.87)0.66 (0.22, 2.0)0.61 (0.22, 1.7)0.53 (0.16, 1.7)0.53 (0.16, 1.8)
1.5 (1.1, 2.1)1.8 (0.75, 4.5)C1.3 (0.83, 2.2)1.0 (0.47, 2.2)1.4 (0.67, 2.8)0.59 (0.39, 0.91)1.2 (0.61, 2.4)1.1 (0.49, 2.6)0.97 (0.44, 2.2)0.98 (0.43, 2.2)
1.1 (0.65, 2.0)1.4 (0.64, 2.9)0.75 (0.46, 1.2)D0.74 (0.31, 1.8)1.0 (0.44, 2.5)0.44 (0.23, 0.83)0.90 (0.38, 2.0)0.84 (0.43, 1.7)0.73 (0.28, 1.9)0.73 (0.28, 1.8)
1.5 (0.67, 3.4)1.8 (0.57, 5.9)1.0 (0.46, 2.1)1.3 (0.54, 3.3)E1.4 (0.49, 4.0)0.59 (0.24, 1.4)1.2 (0.43, 3.3)1.1 (0.36, 3.5)0.97 (0.32, 3.0)0.98 (0.32, 3.0)
1.1 (0.55, 2.2)1.3 (0.42, 4.2)0.72 (0.35, 1.5)0.96 (0.41, 2.3)0.71 (0.25, 2.0)F0.42 (0.18, 0.99)0.86 (0.32, 2.3)0.81 (0.27, 2.5)0.70 (0.24, 2.1)0.70 (0.24, 2.1)
2.6 (1.5, 4.4)3.1 (1.2, 8.3)1.7 (1.1, 2.6)2.3 (1.2, 4.3)1.7 (0.71, 4.1)2.4 (1.0, 5.4)G2.1 (0.90, 4.5)1.9 (0.75, 4.9)1.7 (0.67, 4.0)1.7 (0.66, 4.1)
1.3 (0.61, 2.7)1.5 (0.50, 4.6)0.83 (0.42, 1.7)1.1 (0.49, 2.6)0.83 (0.30, 2.3)1.2 (0.43, 3.1)0.49 (0.22, 1.1)H0.94 (0.32, 2.8)0.81 (0.29, 2.3)0.81 (0.28, 2.3)
1.4 (0.55, 3.3)1.6 (0.59, 4.5)0.89 (0.38, 2.0)1.2 (0.60, 2.3)0.88 (0.28, 2.8)1.2 (0.41, 3.7)0.52 (0.20, 1.3)1.1 (0.36, 3.1)I0.86 (0.27, 2.7)0.87 (0.26, 2.8)
1.6 (0.67, 3.7)1.9 (0.58, 6.3)1.0 (0.46, 2.3)1.4 (0.54, 3.5)1.0 (0.34, 3.1)1.4 (0.48, 4.2)0.61 (0.25, 1.5)1.2 (0.43, 3.5)1.2 (0.37, 3.6)J1.0 (0.32, 3.1)
1.6 (0.66, 3.7)1.9 (0.57, 6.4)1.0 (0.46, 2.3)1.4 (0.55, 3.6)1.0 (0.34, 3.1)1.4 (0.48, 4.2)0.60 (0.24, 1.5)1.2 (0.43, 3.5)1.2 (0.36, 3.8)1.0 (0.32, 3.1)K
  1. A = Tax, B = Cap, C = Bev + Tax, D = Bev + Cap, E = Bev + Exm, F = Mot + Tax, G = Bev + Tax+Cap, H = Bev + Cap+Cyc, I = Bev + Cap+Vin, J = Bev + Tax+ Eve, K = Bev + Tax+Tre
  2. The values represent HR (95%CI), and the values in bold represent HR (95%CI) has significant statistical difference in indirect comparison
  3. Bev bevacizumab, Cap capecitabine, Tax taxanes, Vin vinorelbine, Cyc cyclophosphamide, Exm exemestane, Eve everolimus, Tre trebananib, Mot motesanib
\